Agree, both cambridge companies..@kendal square
having lived in cambridge area for past 15 years.. even most of employees are former employees of each other.. it will be good culturally fit..
All big biotechs beat big time and raise guidance for FY2016...
Biogen lacked execution and mgmt raised false expectation....they deserved to be punished...
Hope is for some activist investors...look what it has done to Amgen..cutting expenses and acquiring small biotechs
If deal goes it goes to 188
if No deal .. it gets $1.8 billion break up fee...add that to next yr earnings.. still would around 150-175 range....no brainer to buy in either scenarios
yes,, i sold few 210-240 puts today...avg price $16....good premium ..it was trading at $4-5 range on thurs.....i believe worst is priced in....it is now trading at big pharma multiple more like MRK/PFE...at PEG ratio of 1.0
this is not going anywhere between 300-330..... JP morgan/Morgan Stanley all said this mgmt team needs to do urgent fix... may be cost structuring.. u can't build manufacturing facility in switzerland Vs choosing Ireland...talking about cost controls....
Sell puts 210-240 range, selling at good premium ...if it gets there u will own this at price...which is absolute steal.. it won't get there...only if MS franchise collapses and no pipeline success.,...
this what happens when we have PhDs running company.. she should lead R&D, engineering.. financial & management should be done with someone who can speak WS language...
look the google CFO recent hore... wall st exec, she knows what analyst wall street lingo
For last 3 years, BIIB management was giving 14-7% growth for next 3-4 years, if it cuts in half, there is loss in credibility..wall street doesn't know what is the multiple of stock..it will take time to settle...
estimates will come down.. look at Allergan ( AGN) exploring split of companies to max/. shareholder wealth, same for CELG and ALXN made big acquisition. The problem with Biogen is the management....
$2.0 dividend/share with 10% per year growth till 2020...$18 billion backlog...85% fee based earnings .. Long term contracts .. $25 billion tax benefits over next 20 years due to asset depreciation ..
Negative is highly leveraged .. That's very normal for asset based companies like railroads , pipelines , utilities..anything that has hard physical assets
....time to load if it holds....
goes to 135
highly overpriced, write to the Alexion investor relations....they paid premium for pipeline..but that's if and buts'
...or something we don't know/.
We keep our 12-month target at $146 on a below peers 1.1X PE-to-growth ratio based on our 2015
EPS estimate. Q1 EPS of $1.07 vs. $0.83 is $0.03 ahead of our estimate. However, sales growth,
including 2% adverse forex impact, of 20.2% was below our 22% growth forecast. Revlimid sales
rose 17%, Abraxane rose 21%, and Pomalyst/Imnovie rose 46%, but Vidaza sales fell 3% on
generic competition. We remain encouraged by the growth of Revlimid and believe further label
expansion will drive continued demand and we see Abraxane sales reaching $1B this year.
...very shareholder friendly mgmt. $7 billion cash on books and increasing, no debt